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A recombinant MnSOD (rMnSOD) synthesized by speciﬁc cDNA
clones derived from a liposarcoma cell line was shown to have the
same sequence as the wild-type MnSOD expressed in the human
myeloid leukaemia cell line U937, except for the presence of the
leader peptide at the N-terminus. These results were fully con-
ﬁrmed by the molecular mass of rMnSOD as evaluated by ES/MS
analysis (26662.7 Da) and the nucleotide sequence of the MnSOD
cDNA. The role of the leader peptide in rMnSOD was investigated
using a ﬂuorescent and/or 68Gallium-labelled synthetic peptide.
The labelled peptide permeated MCF-7 cells and uptake could be
inhibited in the presence of an excess of oestrogen. In vivo it was
taken up by the tumour, suggesting that the molecule can be used
for both therapy and diagnosis. The in vitro and in vivo pharma-
cology tests conﬁrmed that rMnSOD is only oncotoxic for tumour
cells expressing oestrogen receptors. Pharmacokinetic studies in
animals performed with 125I- and 131I-labelled proteins conﬁrmed
that, when administered systemically, rMnSOD selectively
reached the tumour, where its presence was unambiguously dem-
onstrated by scintigraphic and PET scans. PCR analysis revealed
that Bax gene expression was increased and the Bcl2 gene was
down regulated in MCF7 cells treated with rMnSOD, which sug-
gests that the protein induces a pro-apoptotic mechanism.
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Chromosomal abnormalities have long been known to be
involved in cancer development. However, only with the advances
made in cytogenetics and molecular biology in the last 2 decades
was the genetic basis of neoplasia ﬁrmly established and chromo-
somal alterations recognized as being critical in the pathogenesis
of human cancer. Chromosomal changes frequently involve proto-
oncogenes and their deregulation is associated with the develop-
ment of malignancy.1–3 Recurrent chromosomal alterations pro-
vide cytological and molecular markers for the diagnosis and
prognosis of the disease. They also facilitate the identiﬁcation of
genes that are important in carcinogenesis and that may eventually
lead to the development of a targeted drug therapy. Most of the
genetic alterations found in cancer cells are caused by chromo-
somal translocations. When 2 or more chromosomes split and 1 or
more fragments are exchanged among them, chromosomes are
rearranged and the corresponding gene products (i.e., fusion or
hybrid proteins) can fulﬁl new functions or undergo loss of func-
tion, all in order to maintain the malignant phenotype.4 In this
sense it is likely that the molecular basis of tumours rests on pro-
teins derived from chromosomal aberrations that give tumour cells
selective clonal advantages in order to maintain the transformed
phenotype and to escape homeostatic control. An example of these
selective advantages is seen in the expression of proteins such as
the metalloproteinases that are produced and released by tumour
cells and are active in the degradation of basal membranes, and
thus playing a crucial role in tumour metastasis and angiogenesis.5
Cancer cells also provide themselves with environmental advan-
tages such as new blood vessels to get a better supply of oxygen
and nutrients.6 One means by which tumours achieve this goal is
through the activation of the oxidative stress system. It was shown
that nitric oxide synthetase7 and gp91phox,8 2 free radical-generat-
ing enzymes, trigger vascular endothelial growth factor production
and promote oncogenesis. The crucial role of proteins in maintain-
ing the transformed phenotype, along with the striking interde-
pendence of protein structure and protein functions in cancer cells,
prompted us to investigate a liposarcoma cell line that produced
and released a number of proteins used for autocrine growth in
culture medium.9 Among these, a novel isoform of manganese
superoxide dismutase (LSA-type MnSOD) was recently identi-
ﬁed.10 In addition to the enzymatic activity common to all SODs
directed to transform free radicals into hydrogen peroxide,11–13
the LSA-type MnSOD showed peculiar structural and functional
properties that are different from the corresponding native
MnSOD molecule expressed in the human myeloid leukaemia cell
line U937 (Swiss Prot. Code P04179).14 The LSA-type MnSOD,
in fact, is secreted by LSA cells whereas native MnSOD is located
in the mitochondrial matrix.15 The molecular weight of the LSA-
type MnSOD is about 30 kDa, as estimated by SDS-PAGE,10
which is signiﬁcantly higher than the value of 24 kDa calculated
for human native MnSOD.16 Finally, and more importantly, when
injected in vitro or in vivo, the LSA-type MnSOD permeates and
selectively kills tumour cells, provided that they express oestrogen
receptors and low levels of catalase. In contrast, normal cells are
not affected by the protein, making the cytotoxic activity of LSA-
type MnSOD speciﬁc for tumour cells.10 Therefore, a recombinant
form of LSA-type MnSOD (rMnSOD) was produced from speciﬁc
cDNA clones and demonstrated to retain both the structural and
oncotoxic properties of the native protein.10 In this article we char-
acterize the biophysical and biochemical properties of rMnSOD
and report on its pharmacokinetic properties and biodistribution
in vivo. A possible mechanism of action is also proposed. The
detailed structural investigation clearly indicated that rMnSOD
has the same sequence as the native protein. However, both the
recombinant and the original LSA-type MnSOD form carry the
24-residue leader peptide at the N-terminus. These results were
fully conﬁrmed by the molecular mass of rMnSOD, as evaluated
by mass spectrometry (26662.7 Da), and the nucleotide sequence
of the corresponding cDNA. The role of the leader peptide was
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investigated using a ﬂuorescent and/or 68Gallium-labelled syn-
thetic peptide. The labelled peptide showed the same properties as
the whole rMnSOD molecule. It could be speciﬁcally taken up by
ER1 MCF-7 cells or tumour cells in dogs with spontaneous mam-
mary tumours. A radiolabelled version of rMnSOD showed a spe-
ciﬁc and selective ability to reach tumours expressing oestrogen
receptors in tumour-bearing animals and to induce massive cyto-
toxic effects in the target cells. According to our data, these mole-
cules might be suitable for use as anticancer agents, tumour
markers for imaging analysis and even as radiopharmaceutical
vehicles. Finally, PCR analyses indicated that Bax gene expression
was induced and the Bcl2 gene down regulated in treated MCF7
cells, suggesting a pro-apoptotic effect of rMnSOD.
Material and methods
Antibodies and reagents
Primary antibodies. MnSOD-speciﬁc sheep polyclonal anti-se-
rum raised against highly puriﬁed MnSOD from human liver does
not cross-react with Cu/ZnSOD in double-diffusion tests (Calbio-
chem #574596, Germany).
Secondary antibodies. As secondary antibodies, 15-nm colloi-
dal gold-coupled donkey anti-sheep IgGs (Aurion, The Nether-
lands) and horseradish peroxidase-coupled rabbit anti-sheep IgGs
(Promega, Germany) were used.
Immunoafﬁnity puriﬁcation of E. coli recombinant rMnSOD
Bacteria were washed in PBS and lysed in buffer A (4.29 mM
Na2HPO4, 1.47 mM KH2PO4, 2.7mM KCl, 137 mM NaCl,
0.5mM PMSF, pH 7.3) using a cell disrupter (Constant Systems
Ltd, Mode code 01/40/AA). The supernatant (extract) was col-
lected after centrifugation of the lysates for 15 min at 13,200
r.p.m. in an Eppendorf F452411 rotor at 4C. The extract was
loaded onto a T7 tag antibody agarose resin (Novagen), equili-
brated and washed in buffer A. This was then eluted with 100 mM
citric acid, pH 2.2. The collected fractions were neutralized with
2 M Tris base, pH 10.4, and aliquots were analyzed by 12%
polyacrylamide SDS-PAGE.
Characterization of full-length rMnSOD
Native and chemically modiﬁed rMnSOD were desalted by
using HP 1100 HPLC (Agilent Technologies) with a C4 narrow-
bore reverse-phase column (Phenomenex 250 3 2.00 mm2) at a
ﬂow rate of 200 lL/min. Mobile phase was 0.1% triﬂuoroacetic
acid (eluent A) and 95% acetonitrile, 0.07% triﬂuoroacetic acid
(eluent B). Protein samples were reduced with a 10-fold molar
excess of DTT over all SH groups by incubation for 2 hr at 37C
in 6 M Guanidinium/HCl, 250 mM Tris/HCl, 1.2 mM EDTA
buffer, pH 8.5. Carboxyamidomethylation of cysteine residues
was performed by applying a 10-fold molar excess of iodoacet-
amide over all the SH groups for 30 min at room temperature in
the dark. The molecular mass of native, reduced and carboxyami-
domethylated rMnSOD was determined by electrospray mass
spectrometry (ESMS) on a Quattro-Micro triple quadrupole mass
spectrometer (Waters-Micromass). Protein solution was injected
into the ion source at a ﬂow rate of 10 lL/min. Data were proc-
essed using the Mass Lynx program (Waters-Micromass). The N-
terminal amino acid sequence of rMnSOD was obtained by Edman
degradation on an automated Procise H49 sequencer (Applied
Biosystems).
Peptide mapping of rMnSOD
Aliquots of rMnSOD were individually hydrolyzed by incuba-
tion with different proteases (trypsin, endoprotease Lys-C, and
endoprotease V8) at 37C overnight in 50-mM NH4HCO3 buffer,
pH 8.0, using a 1/50 (w/w) enzyme to substrate ratio. The resulting
peptide mixtures were directly analyzed by MALDI mass spec-
trometry. MALDI mass spectra were recorded on a Voyager DE-
PRO mass spectrometer equipped with a reﬂectron analyzer oper-
ating in delayed extraction mode (Applied Biosystem). An amount
of 1 lL of peptide sample was mixed with an equal volume of a-
cyano-4-hydroxycynnamic acid as matrix [in acetonitrile/50-mM
citric acid (70:30, v/v)], applied to the metallic sample plate, and
air dried. Mass calibration was performed by using the standard
mixture provided by the manufacturer. Peptides obtained from
endoprotease V8 digestion were also fractionated by HPLC, using
a C18 narrow-bore reverse-phase column (Phenomenex 250 3
2.00 mm2) at a ﬂow rate of 200 lL/min. Collected fractions were
directly analysed by MALDI mass spectrometry and selected sam-
ples were sequenced by Edman degradation.
Characterization of LSA-type MnSOD
Start material (LSA-CM) was prepared as previously
described10 and then concentrated 12-fold by ultraﬁltration
through Amicon ﬁlters to a cut-off point of 3,000 Da. Proteins
were fractioned by discontinuous 12% SDS-PAGE and blotted
onto nitrocellulose membranes according to Ref. 17. The protein
of interest (LSA-type MnSOD) was incubated in a 1:300 dilution
of anti-MnSOD anti-serum in 10% dry milk/PBS and stained
using horseradish peroxidase-conjugated donkey anti-sheep IgG
and then detected by ECL (Perkin-Elmer, Germany).
LSA-type MnSOD protein band was excised from the gel and
destained by repeated washings with 50-mM NH4HCO3, pH 8.0
and acetonitrile. The sample was reduced and carboxyamidome-
thylated with 10-mM DTT and 55-mM iodoacetamide in 50-mM
NH4HCO3 buffer, pH 8. The alkylated sample was digested at
37C overnight using 100 ng of trypsin. The peptide mixture was
fractionated by LCMSMS analysis, performed on a Q-TOF hybrid
mass spectrometer equipped with a Z-spray source and coupled
on-line with a capillary chromatography system CapLC (Waters,
Manchester, UK). After loading, the peptide mixture (6 lL) was
ﬁrst concentrated and washed at 10 lL/min onto a reverse-phase
pre-column using 0.2% formic acid as eluent. The sample was
then fractionated onto a C18 reverse-phase capillary column (75
lm 3 20 mm) at a ﬂow rate of 250 nL/min using a linear gradient
of eluent B (0.2% formic acid in 95% acetonitrile) in A (0.2% for-
mic acid in 5% acetonitrile) from 7 to 60% in 50 min. The mass
spectrometer was set up in a data-dependent MS/MS mode where
a full-scan spectrum (m/z acquisition range from 400 to 1,600 Da/
e) was acquired and then a tandem mass spectrum (m/z acquisition
range from 100 to 2,000 Da/e). Peptide ions were selected as the 3
most intense peaks of the previous scan. Suitable collision energy
was applied, depending on the mass and charge of the precursor
ion. ProteinLynx software, provided by the manufacturers, was
used to analyze raw MS and MS/MS spectra and to generate a
peak list, which was introduced into the Mascot MS/MS ion
search software for protein identiﬁcation.
Determination of rMnSOD nucleotide sequence
To verify the identity of the rMnSOD, we sequenced the entire
coding region of the gene cloned in the pET 21A1 plasmid. To
sequence the cDNA inserted in the Eco R1 restriction site of the
polylinker, we used the T7 promoter and T7 terminator primers
localized at the 50 and 30 of the vector’s multiple cloning site,
respectively. Moreover, we used, for the sequence analysis, an in-
ternal primer (SOD500/AGCTGACGGCTGCCATCTGTT)
located 269 bases upstream of the stop codon to conﬁrm the exact
nucleotide sequence encoding to the protein C-terminus.
Determination of MnSOD enzymatic activity and hydrogen
peroxide concentration in rMnSOD-treated target cells
To measure MnSOD activity in target cells, exponentially
growing MCF-7 and MRC-5 cultures (2 3 107 cells) were treated
or not treated with 1.5-lM rMnSOD for 24 hr and the MnSOD ac-
tivity assayed using a commercially available SOD assay kit (Cal-
biochem, Darmstadt, Germany) according to the manufacturer’s
instructions. Commercially available recombinant SOD (Sigma-
Aldrich, Germany) and concentrated LSA-CM were used as con-
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trols. Hydrogen peroxide concentrations were measured in 3 3
105 cells from similarly treated cultures, using a commercially
available kit (TEMA, Bologna, Italy) according to the manufac-
turer’s recommendations. This kit is based on a biochemical color-
imetric reaction of xylenol orange in an acid environment contain-
ing sorbitol and ammonium iron sulphate. Upon addition or pro-
duction of hydrogen peroxide the intensity of the colour changes
proportional to the H2O2 concentration.
Circular dicroism
Circular dicroism (CD) spectra were recorded with a Jasco J-
715 spectropolarimeter equipped with a Peltier-type temperature
control system (model PTC-348WI). CD was calibrated using
(1S)-(1)-10-camphorsulphonic acid (Aldrich, Milwaukee, WI),
which exhibits a 34.5 M/cm molar extinction coefﬁcient at
285 nm and 2.36 M/cm molar ellipticity at 295 nm. Before the
measurements, the sample was equilibrated at the desired tem-
perature for 5 min. The molar ellipticity per mean residue, [k]
(deg cm2 dmol21), was calculated according to the equation [k]
5 [k]obs(mrw)/10lC, where [k]obs is the ellipticity (deg), mrw is
the mean residue molecular weight, 111 Da, C is the protein con-
centration (g mL21) and l is the optical path length of the cell
(cm). A 0.1-cm path length cell and a protein concentration of
about 0.05 mg mL21 in 20-mM ammonium triﬂuoracetate, pH
7.8, were used. CD spectra were recorded with a time constant
of 4 s, a 2-nm bandwidth and a scan rate of 5 nm min21. Four
spectra were averaged after baseline correction by subtracting a
buffer spectrum. The percentages of secondary structures were
calculated by using online CD analysis, DICHROWEB (http://
www.cryst.bbk.ac.uk/cdweb/html/), which provides several
algorithms to analyze the curves. CD data were analyzed by 3
different programs: CDSSTR, which implements the variable
selection method by performing all possible calculations with a
ﬁxed number of proteins from a reference set; SELCON3, which
incorporates a self-consistent method together with the singular
value decomposition algorithm (SVDA) to assign protein sec-
ondary structure; and CONTIN/LL, which implements the ridge
regression algorithm of Provencher and Glockner, incorporating
the locally linearized model of Van Stokkum. Far-UV CD at 222
nm was used to monitor thermal unfolding of the protein. The
temperature was raised from 15 to 110C at a rate of 0.5C/min.
At the end of each experiment, the sample was cooled immedi-
ately to room temperature and spectra were recorded to monitor
the extent of re-folding. The denaturing temperature (Tm) was
estimated to be 59 6 2C from the ﬁrst derivative of the CD data
as a function of temperature. Protein solution was analyzed for
total metal content by ﬂame atomic absorption spectrometry.
Manganese concentration was determined by comparison with a
calibration curve. A Varian SpectrAA 220 atomic absorption
spectrometer equipped with an MK7 burner was used for the
analyses.
Immunocytochemistry: Light microscopy
Tumour cells were ﬁxed in Zamboni solution (4% paraformal-
dehyde, 15% picric acid) for 15 min, washed with PBS and
blocked for an additional 15 min in PBS containing 1% bovine se-
rum albumin (BSA) and 0.15% glycine. For immunodetection the
cells were incubated with a 1:20 dilution of sheep anti-MnSOD
anti-serum at 4C overnight, followed by further incubation with
10 nm colloidal gold-coupled donkey anti-sheep IgGs for 2 hr at
room temperature. By treating the samples with silver enhancer
for 6 min (Sigma-Aldrich, Germany), antibody complexes were
revealed, which were then rinsed in sodium thiosulphate and dis-
tilled water and counterstained with Mayer’s haemalum solution.
These samples were examined using the Kontron Electronic Imag-
ing Computer System KS300. Imaging was performed using a
Kontron Electronic Progress 3008 camera.18
Inhibition of rMnSOD uptake in MCF-7 cells by estradiol:
immunocytochemical determination
MCF-7 cells were seeded in 2 different chamber slides contain-
ing 16 well/chamber (NUNC) in DMEM supplemented with 10%
FCS at a density of 5,000 cells/well and incubated at 37C. After
24 hr, the test cells were treated with a 1.5-lM rMnSOD and a
cold 10-nM estradiol solution in DMEM supplemented with 10%
FCS. Control cells were treated with DMEM 1 10% FCS 1 1.5-
lM rMnSOD and DMEM 1 10% FCS, respectively. Experiments
were performed in triplicate.
Radiolabelling and biodistribution of rMnSOD
rMnSOD was labelled with 125I or 131I, using IODO-GEN pre-
coated iodination tubes (Pierce, Rockford, IL) according to the
manufacturer’s suggested procedure. Brieﬂy, 200 lg of protein
were added to the iodination tubes in a 200-lL volume of phos-
phate-buffered saline. To the protein solution we added 500 lCi of
Na-125I (Amersham Biosciences UK Limited, Buckinghamshire,
UK) and incubated this for 15 min. Labelled protein was recovered
by gel ﬁltration on D-salt polyacrylamide columns (Pierce). Label
incorporation was 90%. Biodistribution was measured in a tumour-
bearing dog as described in the legend to Figure 4.
Synthesis of rMnSOD leader peptide in solid phase
The 24-residue leader peptide MLSRAVCGTSRQLAPAL-
GYLGSRQ sequence and a scrambled peptide sequence
QSRMLSCTGRAVLRGLGYLLASQPAGG were synthesized
using the solid-phase approach and standard Fmoc methods in a
manual reaction vessel. The samples were puriﬁed by semi-prepa-
rative RP-HPLC using C18-bonded silica column (Vydac
218TP1010). The puriﬁed peptide was 99% pure as determined by
analytical RP-HPLC. The correct molecular mass of the peptide
was conﬁrmed by mass spectrometry and amino acid analysis.19
Confocal analysis
MCF7-cells cultivated in glass bottom polystyrene dishes were
incubated with 1.5-lM FITC-labelled peptide for 1 hr at room
temperature, washed with PBS, incubated in 2% paraformalde-
hyde-PBS for 1 hr at room temperature, and washed with PBS.
The labelled cells were analyzed using a Zeiss LSM 510 confocal
laser scanning microscope. Control cells were treated ﬁrst with
1-lM oestrogen and then processed in the same manner as the
treated cells. Fluorescent images were analyzed with the Meta
Morph Imaging System software (Universal Imaging Corporation,
West Chester, PA).
Radioisotopes
131I was purchased from Amersham and 68Gallium was synthe-
sized by the Department of Nuclear Medicine of the National Can-
cer Institute (Naples, Italy).
Radiolabelling with 68Ga-labelled DOTA-coupled
leader peptide and PET imaging
Approximately 20 lg of DOTA-coupled MLSRAVCGTSRQ
LAPALGYLGSRQ peptide, corresponding to the leader sequence
of rMnSOD, were labelled with 68Ga at 120C for 15 min in
Hepes buffer. The labelled peptide was puriﬁed by passing it
through a C18 reversed-phase cartridge which was washed with
water and subsequently air dried. The peptide was recovered with
400 lL of 96% ethanol. Then, 1 mCi of the labelled peptide was
injected intravenously into the front-limb of a 13-year-old female
mongrel dog weighing 15 kg that had been referred by the Depart-
ment of Medicine and Surgery, Faculty of Veterinary Medicine,
University of Naples, Federico II. The animal was affected by
spontaneous multiple breast cancer lesions. Informed consent was
obtained from the dog’s owner prior to performing the PET stud-
ies and rMnSOD treatments. Images were acquired 30 min after
injection on a Siemens ECAT 47 PET scanner. Images were
reconstructed in the transaxial, coronal and sagittal planes.
2686 MANCINI ET AL.
PCR analyses
Three samples of MCF7 breast cancer cells were cultured for 4
hr in DMEM 10% FCS containing 1.5-lM rMnSOD. Three con-
trol samples consisting of MCF-7 cells in the absence of rMnSOD
were maintained in identical culture conditions. Total RNA was
extracted from MCF-7 cells cultured in the presence or in the ab-
sence of rMnSOD (Chomczynski and Sacchi procedure, RNAzol,
Invitrogen) according to the manufacturer’s instructions, and its
integrity was veriﬁed by agarose gel electrophoresis.
From each of the 6 samples 2 lg of total RNA in a ﬁnal volume
of 20 lL was reverse-transcribed by Avian myeloblastosis virus
(AMV) reverse transcriptase (Gibco BRL Invitrogen) according to
the manufacturer’s instructions at 37C for 60 min using random
hexamer primers. PCR analysis of both Bax and Bcl2 gene expres-
sion was performed by using a Gene Amp PCR system 9700
(Applied Biosystem) and hot start Taq Gold (Applera). Actin was
used as a housekeeping control gene. The following primers were
used: Bax Fw CCA GCT CTG AGC AGA TCA TG; Bax Rw
AAG ATC CTG GCA GAG AGG AG; Bcl2 Fw GAC TTC GCC
GAG ATG TCC AG; Bcl2 Rw CAG GTG CCG GTT CAG GTA
CT; Actin Fw GAC TAC CTC ATG AAG ATC CT; and Actin
Rw GCT TGC TGA TCC ACA TCT GC. PCR conditions were:
initial denaturation at 95 for 10 min followed by 35 cycles: 95,
450’; 54 , 450’ and 72 450’ with a ﬁnal extension at 72 for
10 min. The ampliﬁcation products were fractionated on a 1%
agarose gel in 0.5 3 TBE (Tris Borate EDTA) buffer to control
the amplicon lengths.
Results
Immunoafﬁnity puriﬁcation of rMnSOD
Human T7-tagged rMnSOD was puriﬁed from E.coli cell
extract through a single immunoafﬁnity chromatography step on a
T7 tag antibody agarose column equilibrated and washed in phos-
phate buffer. The retained proteins were eluted by lowering the
pH to 2.2 with 100-mM citric acid. Collected fractions were neu-
tralized with 2-M Tris base, pH 10.4, and aliquots were analyzed
by SDS-PAGE to verify the purity grade. Fractions containing a
single protein band were pooled and structurally characterized in
detail.
Characterization of full-length rMnSOD
Puriﬁed native and carboxyamidomethylated rMnSOD samples
were ﬁrst analyzed by ESMS. The native protein exhibited a mo-
lecular mass of 26662.7 6 1.2 Da (Fig. 1a). This mass value
increased to 26895.6 6 0.9 Da following alkylation of the protein
with iodoacetamide, with a mass difference of 232.8 Da corre-
sponding to four carboxyamidomethyl groups that were incorpo-
rated, and hence revealing the occurrence of four cysteine resi-
dues. The N-terminal sequence of the ﬁrst 20 amino acids of
rMnSOD, as determined by automated Edman degradation, con-
ﬁrmed the presence of the entire T7 tag (15 amino acids) at the N-
terminus of the protein. The other 5 residues corresponded to the
leader peptide of human MnSOD, indicating that the puriﬁed pro-
tein had not been proteolytically processed. The human MnSOD
sequence reported in the Swiss Prot database (code: P04179)
encompasses 221 residues (without the N-terminal Met), including
a 24-residue leader peptide for mitochondrial import, and contains
3 Cys residues. This sequence accounts for a molecular mass of
24722.1 Da. When including the 15-residue peptide tag, the theo-
retical mass value for rMnSOD (236 residues) increases to
26247.6 Da.
Peptide mapping of rMnSOD and LSA-type MnSOD
Peptide mapping of rMnSOD was carried out using 3 different
proteases (trypsin, endoprotease Lys-C and endoprotease V8). Ali-
quots of the reduced and carboxyamidomethylated recombinant
protein were individually digested with the 3 enzymes and the
resulting peptide mixtures directly analyzed by MALDI mass
spectrometry. Mass signals recorded in the spectra were assigned
to individual peptides within the rMnSOD sequence according to
their molecular mass and the speciﬁcity of the proteases (Fig. 1b).
The MALDI mass spectra demonstrated an almost complete cov-
erage of the protein sequence from the N-terminal amino acid to
residue 236. However, as stated above, the protein sequence con-
ﬁrmed by the mass mapping procedure did not account for the ex-
perimental mass value determined by ESMS. Taken together,
these data suggest that the peptide extension might have been
located at the C-terminus. Moreover, 2 mass signals at m/z 1431.6
and 1874.9 in the MALDI spectra that were obtained after endo-
protease V8 digestion could not be assigned to any peptide within
the rMnSOD sequence, suggesting that these fragments might
FIGURE 1 – Structural analysis of rMnSOD. Electrospray mass spectrometry (ESMS) analysis of recombinant rMnSOD showing the accurate
molecular mass of 26662.7 6 1.2Da (a). MALDI/MS analysis of the rMnSOD endoprotease V8 digestion products. Assignment of mass signals
to individual peptides within the protein sequence is indicated (b).
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very likely contain the additional amino acid residues. The endo-
protease V8 digestion product was then fractionated by HPLC and
the individual fractions were manually collected and directly ana-
lyzed by MALDI mass spectrometry. The fraction containing the
peptide with a mass value of 1431.6 Da was identiﬁed and submit-
ted to automated Edman degradation and demonstrated the follow-
ing amino acid sequence: ArgTyrMetAlaCysLysAsnLysAsn-
SerCys. This sequence indeed corresponded to the C-terminal pep-
tide of rMnSOD from 231 to 236 plus the additional 5-residue
sequence Asn-Lys-Asn-Ser-Cys. This extension contained the
fourth cysteine residue predicted previously by ESMS analysis.
Moreover, the calculated molecular mass of the rMnSOD includ-
ing the C-terminal extension (26666.2 Da) was in perfect agree-
ment with the experimental value determined by ESMS.
Once the recombinant form of MnSOD was characterized, the
structural analysis was also extended to the LSA-type MnSOD,
the isoform secreted by LSA cells and endowed with anti-tumou-
ral activity.10 The LSA-secreted proteins were fractionated by
SDS-PAGE and the protein band likely corresponding to the
MnSOD was excised from the gel, digested in situ with trypsin
and identiﬁed by using LC-MS/MS methods.20 Once the exact
electrophoretic mobility of LSA-type MnSOD was established, a
peptide map of the secreted protein was constructed by tryptic
digestion of the corresponding gel band. The resulting peptide
mixture was directly analyzed by MALDI mass spectrometry and
the mass signals recorded in the spectra were assigned to individ-
ual peptides within the rMnSOD sequence according to their mo-
lecular mass and the speciﬁcity of the proteases as described
above for rMnSOD. Peptide mapping of the LSA-type MnSOD
essentially conﬁrmed the presence of the leader peptide at the N-
terminus of the protein. In fact, the mass signals at m/z 2464.6 and
2333.4 corresponded to the N-terminal peptide of the MnSOD pre-
cursor form with and without the initial Met residue. As expected,
the C-terminal end of the LSA secreted protein did not show the
additional 5-amino acid peptide, as indicated by the mass signal at
m/z 816.5 corresponding to the oxidized form of the C-terminal
peptide 217-222.
Sequence analysis of rMnSOD
The entire coding region of the gene for rMnSOD was veriﬁed
by cDNA sequencing. The T7 promoter and T7 terminator primers
localized at 50 and 30 of the vector’s multiple cloning site were
used to sequence the cDNA inserted in the Eco R1 restriction site
of the polylinker (Table I). Moreover, an internal primer located at
position 500 of the coding sequence was used to conﬁrm the exact
nucleotide sequence corresponding to the 5 additional amino acids
at the protein’s C-terminus (Table I). The data obtained from the
ﬁne sequence analysis clearly demonstrated that a single point
mutation had occurred after the codon corresponding to Lys 221
of the protein sequence, generating a new stretch of 5 codons:
AAT AAG AAT TCA TGT corresponding to the amino acids N K
N S C. The addition of these amino acids was due to the loss of a
G in position 666 in the cDNA sequence either during cloning or
ampliﬁcation of the rMnSOD cDNA. The loss of this base gener-
ated a frame shift in which the last Lys codon normally present in
the human MnSOD sequence was modiﬁed and the terminator
codon TAA lost. Translation proceeded using the nucleotides of
the vector and this shift produced the additional 5 amino acids
(Table I).
CD
Figure 2a shows the CD spectrum of the protein characterized
by a strong positive band at 192 nm and 2 strong negative bands at
210 and 222 nm. Quantiﬁcation of the overall secondary structure
of rMnSOD (see Material and methods) indicates 50% of a-helix,
15% of b-sheet and 15% of turns. The results are in line with those
determined from the X-ray structure of human MnSOD.21 The
change in ellipticity of rMnSOD at 222 nm with temperature is
plotted in Figure 2b, which indicates an apparent Tm value of
59C, taken as the midpoint of the unfolding transition. Therefore,
this protein is less stable than the human native enzyme. For the
latter, differential scanning calorimetry22 showed the ﬁrst inactiva-
tion step at 68C, followed by a main unfolding transition at about
88C. Metal analysis, performed by atomic absorption spectros-
copy, revealed that about two thirds of the metal binding sites are
occupied by manganese ions.
MnSOD enzymatic activity and hydrogen peroxide
concentration in rMnSOD-treated cells
Intracellular MnSOD activity and hydrogen peroxide produc-
tion were both measured in susceptible MCF-7 and resistant
MRC-5 cells prior to and after rMnSOD treatment. Although
resulting in a modest increase in the overall MnSOD activity of
MCF-7 cells (900 6 8 U/mg to 1,250 6 8 U/mg protein), exoge-
TABLE I – DETERMINATION OF THE NUCLEOTIDIC SEQUENCE OF RECOMBINANT rMnSOD cDNA
acgcgggactcgtggctgtggtggcttcggcagcggcttcagcagatcggcggcatcagcggtagcaccagcactagcagc
ATG TTG AGC CGG GCA GTG TGC GGC ACC AGC AGG CAG CTG GCT CCG GCT TTG GGG TAT CTG
M L S R A V C G T S R G S A P A L G Y L
GGC TCC AGG CAG AAG CAC AGC CTC CCC GAC CTG CCC TAC GAC TAC GGC GCC CTG GAA CCT
G S R Q K H S L P D L P Y D Y G A L E P
CAC ATC AAC GCG CAG ATC ATG CAG CTG CAC CAC AGC AAG CAC CAC GCG GCC TAC GTG AAC
H I N A Q I M Q L H H S K H H A A Y V N
AAC CTG AAC GTC ACC GAG GAG AAG TAC CAG GAG GCG TTG GCG AAG GGA GAT GTT ACA GCC
N L N V T E E K Y Q E A L A K G D V T A
CAG ATA GCT CTT CAG CCT GCA CTG AAG TTC AAT GGT GGT GGT CAT ATC AAT CAT AGC ATT
Q ILE A L Q P A L K F N G G G H I N H S I
TTC TGG ACA AAC CTC AGC CCT AAC GGT GGT GGA GAA CCC AAA GGG GAG TTG CTG GAA GCC
F W T N L S P N G G G E P K G E L L E A
ATC AAA CGT GAC TTT GGT TCC TTT GAC AAG TTT AAG GAG AAG CTG ACG GCT GCA TCT GTT
I K R D F G S F D K F K E K L T A A S V
GGT GTC CAA GGC TCA GGT TGG GGT TGG CTT GGT TTC AAT AAG GAA CGG GGA CAC TTA CAA
G V Q G S G W G W L G F N K E R G H L Q
ATT GCT GCT TGT CCA AAT CAG GAT CCA CTG CAA GGA ACA ACA GGC CTT ATT CCA CTG CTG
I A A C P N Q D P L Q G T T G L I P L L
GGG ATT GAT GTG TGG GAG CAC GCT TAC TAC CTT CAG TAT AAA AAT GTC AGG CCT GAT TAT
G I D V W E H A Y Y L Q Y K N V R P D Y
CTA AAA GCT ATT TGG AAT GTA ATC AAC TGG GAG AAT GTA ACT GAA AGA TAC ATG GCT TGC
L K A I W N V I N W E N V T E R Y M A C
AAA AAT AAG AAT TCA TGT
K N K N S C
Nucleotide sequence of the rMnSOD cDNA inserted in the Eco R1 restriction site of the polylinker.
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nously applied rMnSOD enhanced the hydroxide peroxide levels
in MCF-7 cultures dramatically, as detected in both cell pellets
and medium supernatants. In fact, the H2O2 concentration in
MCF-7 cultures increased from basal levels of 38.3 6 1.8 (cell-
associated) and 0.0 ng/mL (medium) to 322.9 6 2.8 and 690 6
5.4 ng/mL, respectively, after rMnSOD treatment. In contrast, the
cell-associated H2O2 concentrations in resistant MRC-5 cells
remained constant at about 30 ng/mL, regardless of whether cul-
tures had been treated with rMnSOD or not.
In vivo pharmacology
The pharmacological effect of rMnSOD on in vivo tumour
growth was investigated using 60 nude mice bearing A2780 cell
xenografts derived from a human ovarian adenocarcinoma. Two
groups consisting of 6 animals each were used as controls. The
ﬁrst group remained untreated whereas the other received only
PBS by injection. When the size of the tumour mass reached
1.5 cm, the animals were injected intraperitoneally (i.p.) with
increasing daily doses of rMnSOD and tumour growth evaluated
(Table II). From this experiment we could establish the amount of
rMnSOD needed to completely inhibit tumour growth. All these
observations were made over a period of 15 days. The experiments
were stopped at Day 15 because the tumours in the animals of the
control groups grew rapidly, limiting their ability to move, eat and
drink.
Biodistribution of 125I-labelled rMnSOD after injection into
normal and tumour-bearing animals
For biodistribution studies, normal animals or animals bearing
A2780 cell xenografts derived from a human ovarian adenocarci-
noma were injected i.p. with 4 lg of labelled protein (Fig. 3). The
animals were killed 3 hr after injection, dissected and organs
counted in a single-well gamma counter. Dilutions of the injected
compound were also counted to accurately determine the injected
dose. The relative amount of radioactivity in the organs was calcu-
lated and expressed as a percentage of the injected dose/gram
tissue (%ID/g).
Localization of 131I-rMnSOD in a dog with breast cancer
In vivo localization of rMnSOD was monitored by treating a 12-
year-old female dog weighing 23 kg having breast cancer with
500 lCi of 131I-labelled rMnSOD. Scintigraphic images of the ab-
domen (ventral view) obtained 3 and 24 hr after injection are
shown in Figure 4. A mammary tumour, labelled ‘‘T,’’ is clearly
visible in the right lower quadrant in both early and late images.
Non-speciﬁc retention could be detected in liver and stomach (LS)
and in the urinary bladder in the 3-hr image and in the bowel in
the 24-hr image. This shows that the protein could reach and local-
ize at the tumour site with good selectivity even at an early stage
after injection.
Immunocytochemical analyses of rMnSOD-treated MCF
cells in the presence and absence of estradiol
Sensitive MCF-7 cells were then treated with a 1.5-lM concen-
tration of rMnSOD in the presence or absence of a 10-nM solution
of estradiol. MCF-7 cells treated only with DMEM supplemented
with 10% FCS were used as a negative control. After 24 hr, light
microscopy revealed that only the MCF-7 cells treated with an
excess of estradiol and the negative control cells were viable. In
contrast, the MCF-7 cells that received only rMnSOD had all died.
These results were also conﬁrmed by immunocytochemical analy-
ses. After treatment with the solutions reported above, the cells
were ﬁxed and the presence of the rMnSOD inside the cells was
determined by light microscopy following immunogold staining
(Fig 5). In contrast to the untreated MCF-7 cells (A), MCF-7 cells
treated with rMnSOD showed highly cytoplasmic immunoreactiv-
FIGURE 2 – Circular dicroism analysis of rMnSOD. (a) CD spec-
trum of rMnSOD in 20-mM ammonium triﬂuoracetate, pH 7.8, at
10 C. (b) Thermal transition curve obtained by recording the molar
ellipticity at 222 nm.
TABLE II – IN VIVO PHARMACOLOGY
Groups Animals used (N) Treatment Daily dose (lg) Total dose (lg) Tumor size beginning Tumor size end Necrotic areas
1 23 6 None None None 1.5 cm 4.4 cm Absent
2 12 rMnSOD 1 15 1.5 cm 3.2 cm 1
3 12 rMnSOD 2 30 1.5 cm 2.3 cm 11
4 12 rMnSOD 3 45 1.5 cm 1.9 cm 111
5 12 rMnSOD 4 60 1.5 cm 1.3 cm 1111
Evaluation of tumour growth in nude mice bearing A2780 cell xenografts derived from a human ovarian adenocarcinoma and treated or not
treated with intraperitoneal injection of increasing daily doses of rMnSOD. Control groups consisting of 6 animals each were untreated or
received only PBS by injection.
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ity 1 hr after (B) and 2 hr after (B1) the rMnSOD treatment, dis-
playing a ghost-like feature indicating early necrosis and the cyto-
plasm ﬁlled with silver-enhanced immunogold particles. The same
high immunoreactivity against the rMnSOD was detected outside
the MCF-7 cells that were pre-incubated with an excess of estra-
diol. In this case the internalization of rMnSOD was impaired (C).
The immunoreaction was found to be clearly negative when the
MCF-7 cells were treated only with estradiol (C1)
Cytotoxic effect of rMnSOD on MCF-7 cells
pre-treated with estradiol
rMnSOD was added to the culture medium of sensitive MCF-7
cells at a ﬁnal concentration of 1.5 lM, in the presence and ab-
sence of a 10-nM estradiol solution in DMEM supplemented with
10% FCS. The cytotoxic effect of rMnSOD was evaluated by
measuring the LDH released by lysis from treated cells. In Figure
6 the amount of LDH released into the culture supernatant is
expressed as a percentage of total LDH released from cell lysis
following detergent treatment. Approximately 3% LDH was found
in the medium of the control cultures not treated with rMnSOD.
In vitro analysis with FITC-conjugated leader peptide
The role that the non-excised 24-residue leader peptide might
have in the unusual functions of the rMnSOD was investigated. A
synthetic version of the leader peptide was then constructed and
marked with ﬂuorescein. A scrambled peptide with the same
amino acid composition but a different sequence was also synthe-
sized and used as control. Cultured MCF-7 cells were separately
treated with the labelled leader peptide or the scrambled sequence
for 1 hr at room temperature and then examined by confocal mi-
croscopy. Figure 7a shows the confocal laser scanning microscopy
images of the equatorial sections of MCF-7 cells. Intense cytoplas-
mic ﬂuorescence was clearly detected in the cells incubated with
the leader peptide, demonstrating that the labelled peptide was
able to permeate the cells under these conditions. No ﬂuorescence
was observed within the negative control cells treated with the
scrambled peptide (Fig. 7d). In a different experiment, cultured
MCF-7 cells were previously treated with a 1-lM oestrogen solu-
tion and then incubated with the labelled peptide. Confocal mi-
croscopy examination at the same focal plane of untreated cells
(Fig. 7b) showed only a peripheral ﬂuorescence outside the cells,
conﬁrming that peptide uptake was inhibited in the presence of
oestrogen.
In vivo analysis with 68Ga-labelled DOTA-coupled leader
peptide and PET imaging
The synthetic leader sequence of rMnSOD was previously
coupled with DOTA, labelled with 68Ga and then injected into a
dog bearing a spontaneous mammary tumour. Two hours after the
injection the animal was examined by PET. Sagittal PET images
(Fig. 8) showed a high concentration of the radiolabelled peptide
in the tumour (T). The radiopharmaceutical was eliminated via the
kidneys (K), where, along with the urinary bladder, the highest
concentration of activity was seen in the images, 10 times higher
than in the tumour. In addition the liver (L) showed levels of
uptake that were comparable to those observed in the tumours.
FIGURE 3 – In vivo uptake and biodistribution of rMnSOD. For the biodistribution study, nude mice bearing A2780 cell xenografts derived
from a human ovarian adenocarcinoma were treated or not treated after the tumour was clinically evident, with a daily i.p. injection of 4 lg
rMnSOD. After 15 days of treatment, an animal of each group (treated or not treated) was injected with 5 lg of 125I-labelled rMnSOD to study
the biodistribution. The animals were killed 3 hr after the injection, dissected and organ counted in a single-well gamma counter. Dilutions of
the injected compound were also counted to accurately determine the injected dose. The relative amount of radioactivity in the organs was calcu-
lated and expressed as percentage of the injected dose/gram tissue (%ID/g).
FIGURE 4 – Localization of 131I-labelled rMnSOD in a dog with
breast cancer. Scintigraphic images of the abdomen (ventral view)
obtained 3 and 24 hr after injection of 500 lCi of 131I-labelled
rMnSOD in a 12-year-old female dog weighing 23 kg with breast can-
cer. A mammary tumour in the right lower quadrant is clearly visible
in the early and late images (T). Non-speciﬁc retention is visible in
liver and stomach (LS) and in the urinary bladder in the 3-hr image
and bowel in the 24-hr image.
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PCR analyses
The possible pro-apoptotic effects of rMnSOD on tumour cells
were investigated by PCR expression analysis of the pro-apoptotic
Bax gene and the anti-apoptotic Bcl2 gene. Three samples of
MCF7 breast cancer cells were cultured in DMEM 1 10% FCS in
the presence of 1.5-lM rMnSOD; 3 control samples of MCF-7
cells were maintained under identical culture conditions but in the
absence of rMnSOD. The total RNA extracted from the 6 cell
samples was reverse-transcribed and both Bax and Bcl2 cDNAs
were ampliﬁed by PCR analysis. Figure 9 shows the ampliﬁed
fragments of both Bax (460 bp) and Bcl2 cDNAs (205 bp) in the
different experimental conditions. A strong Bax transcript band
was clearly detected in all the samples of MCF-7 cells cultured in
the presence of rMnSOD (Panel a, lanes a, b and c) that was
absent in the controls. In contrast, Bcl2 gene expression could
only be detected in MCF7 cells in the absence of rMnSOD (Panel
b, lanes d, e and f) whereas its expression was totally impaired by
rMnSOD treatment. The actin transcript band (500 bp) unaffected
by rMnSOD treatment was used to control for the quantity of
cDNA (Panel c).
Discussion
This article reports the biochemical, biophysical and functional
characterization of rMnSOD, a recombinant manganese superox-
ide dismutase produced and actively secreted by a human liposar-
coma cell line cultivated in a chemically deﬁned medium into
which the protein has been released. Both the original LSA-type
MnSOD and the recombinant enzyme were previously found to
exhibit oncosuppressive activity in vitro and in vivo.10 Wild-type
MnSOD is normally located within the mitochondrial matrix fol-
lowing cleavage of the leader sequence and is not endowed with
any oncosuppressive activity.
The active secretion of the LSA-type MnSOD by LSA cells and
its ability to act as an oncosuppressor suggested that certain struc-
FIGURE 5 – Immunocytochemical analysis of rMnSOD-treated cells. Untreated MCF-7 cells (control, a) and MCF-7 cells treated with
rMnSOD for 1 hr (b) and 2 hr (b1), treated with rMnSOD and estradiol (c), and treated only with estradiol (c1) were examined by light micros-
copy after rMnSOD labelling with immunogold and silver enhancer staining. Panel a: cluster of control MCF-7 cells showing the absence of im-
munostaining in the cytoplasm. Panel b: MCF-7 cells 1 hr after rMnSOD administration showing the cytoplasm ﬁlled with silver enhanced
immunogold particles. Panel b1: MCF-7 cells after 2 hr of rMnSOD treatment, displaying a ghost-like feature indicating early necrosis and the
cytoplasm ﬁlled with silver enhanced immunogold particles. Panel c: MCF-7 cell clusters treated with rMnSOD (1.5-lM) and estradiol showing
a large amount of silver-enhanced immunogold particles located in the medium outside the cell. Panel c1: cultured MCF-7 cells treated only
with estradiol showing the absence of immunostaining in the cytoplasm. Scale bar (in c1)5 7 lm.
FIGURE 6 – Cytotoxic effect of rMnSOD on MCF-7cells pretreated with estradiol. The cytotoxic effect of rMnSOD on MCF7 cells in the pres-
ence and absence of estradiol was evaluated by measuring the amount of LDH released in the culture supernatant. rMnSOD-released LDH is
expressed as a percentage of total LDH measured from cells after lysis following detergent treatment.
2691DIAGNOSIS AND THERAPY WITH A HUMAN rMnSOD
tural modiﬁcations might account for these unusual properties. A
detailed structural characterization of the recombinant product
both at the protein and cDNA level clearly demonstrated that
rMnSOD retains the leader sequence at the N-terminus and con-
tains an additional pentapeptide at the C-terminus. Since the pres-
ence of the 5 C-terminal residues was due to a single point muta-
tion during genetic manipulation, the principal difference between
the wild-type MnSOD and rMnSOD was the persistence of the
leader peptide in the recombinant form. The structural analysis
was also extended to the LSA-type MnSOD, the isoform secreted
from LSA cells endowed with anti-tumoural activity,10 conﬁrming
the presence of the leader peptide at the N-terminus and ruling out
the occurrence of an additional pentapeptide at the C-terminus, as
expected. Because the oncotoxic activity is present both in the
original LSA-type MnSOD and in rMnSOD, the presence of the
leader peptide was strongly suspected, not only considering the
FIGURE 7 – Fluorescence confocal microscopic analysis of rMnSOD leader peptide distribution in treated MCF-7 cells. Equatorial sections of
FITC-labelled MCF-7 cells are shown. (a) MCF-7 cell not pre-treated with oestrogen. FITC-labelled peptide permeated the cell and ﬁlled the
entire cytoplasm 1 hr after treatment. (b) MCF-7 cell pre-treated with oestrogen: FITC-labelled peptide remains outside the cell (phase contrast
image in panel (c). (d) Control MCF-7 cell treated with FITC-labelled scrambled peptide and (phase contrast image in Panel e).
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unusual secretion of the molecule from LSA cells as previously
reported9 but also because of the speciﬁc and selective uptake by
tumour cells.
rMnSOD is enzymatically active even in the presence of the
leader sequence, whereas the wild-type enzyme requires that the
leader peptide is released in order to be transformed in the mature,
active form.16 Characterization of the secondary structure and the
stability of the recombinant protein rMnSOD was then investi-
gated. The far-UV CD spectra of rMnSOD indicated that the sec-
ondary structure of the protein is similar to that of human MnSOD
as shown by its crystallographic structure.21 Thermal unfolding of
rMnSOD, also monitored by CD spectra, was followed by an irre-
versible aggregation of the unfolded molecule. The unfolding tem-
perature (59C) is about 30 lower than that of native human
MnSOD. On the basis of the crystal structure of human MnSOD,
the additional peptide fragments present at the N-terminal of
rMnSOD should not interfere with the dimer and tetramer associa-
tion, as they are far away from the subunit interface. The decrease
in the thermal stability of rMnSOD with respect to the wild-type
protein suggests that the subunit fold is destabilized, partly due to
the presence of the leader peptide at the N-terminus and partly to
the partial occupancy of the metal ion-binding sites.23 The inter-
nalized rMnSOD may increase the level of oxidants (hydrogen
peroxide and hydroxyl radicals), which are known to mediate cell
killing.24–26 The addition of rMnSOD to MCF-7 cells generated
increasing amounts of hydrogen peroxide and total SODs inside
the tumour cells. In contrast, the cell-associated H2O2 concentra-
tions in resistant MRC-5 cells remained constant, regardless of
whether cultures had been treated with rMnSOD. Treatment of
MCF-7 cells with a commercially available SOD preparation
(which essentially consists of a mixture of Zn/Cu-SOD and
MnSOD) as control did not provide the same results (data not
shown). These results conﬁrmed that Zn/Cu-SOD is structurally
and functionally different from rMnSOD.27,28 Several reports sug-
gested that MnSOD may have tumour suppressor functions but its
role in cancer development remained elusive although it has long
been known that reactive oxygen species (ROS) are increased in
cancer cells. Indeed, most cells have abundant Cu/Zn-SOD and
glutathione peroxidase (Gpx) to dismutate ROS into molecular ox-
ygen and water, making an anti-cancer mechanism of rMnSOD
questionable. Moreover, previous studies showed increased levels
of both Zn/Cu-SOD and MnSOD in cancer cells of various tissue
origins whereas high levels of MnSOD expression29–31 have been
detected in various primary human cancer tissues and in blood
samples from patients with various types of leukaemia.32 How-
ever, as MnSOD levels seem to decrease in certain cancer cells
and forced expression of MnSOD appears to suppress malignant
phenotypes in certain experimental models, only MnSOD, and not
Zn/Cu-SOD, was considered as a tumour suppressor protein.33
This was supported by the ﬁnding that suppression of MnSOD
expression by siRNA promotes O2
2 accumulation and also cell
proliferation in vitro and tumour growth in vivo.34
In an attempt to deﬁne the mechanism underlying the cytotoxic
effects of rMnSOD, the expression levels of 2 apoptotic genes
were examined by PCR. A strong upregulation of pro-apoptotic
Bax gene expression was clearly observed in tumour cells in the
presence of rMnSOD as compared to the control, suggesting that
treatment with the recombinant protein might induce the apoptotic
cascade in tumour cells. The possible involvement of an apoptotic
mechanism was conﬁrmed by the strong inhibition of anti-apopto-
tic Bcl2 gene expression detected in tumour cells in the presence
of rMnSOD. Although more data are needed to support these con-
clusions, the induction of an apoptotic program might explain the
speciﬁc and selective cytotoxicity exerted by rMnSOD on cancer
cells at the molecular level.
The in vivo analysis demonstrated a dose-dependent cytotoxic
effect of rMnSOD. Biodistribution studies of rMnSOD performed
to investigate its speciﬁc uptake and catabolic excretion provided
information for a more rational pharmacological use of the mole-
cule. These studies aimed to evaluate the in vivo anti-tumoural ac-
tivity of rMnSOD and to investigate which organs would preferen-
tially take up the molecule and, hence, to deﬁne the toxicity risk
of each organ related to the administration of the protein. The 125I-
labelled rMnSOD was injected into nude mice bearing ovarian
carcinomas and the amount of radioactivity incorporated was eval-
uated. The tumours in nude mice showed radioactivity levels 3 or
FIGURE 8 – PET analysis of 68Ga-labelled DOTA-coupled peptide
in a treated tumour-bearing dog. The sagittal view shows a high con-
centration of the radiolabelled peptide in the tumour (T). The radio-
pharmaceutical was eliminated through the kidneys (K) which, along
with the urinary bladder, showed the highest signal in the images,
10 times higher than in the tumour. The liver (L) showed levels of
uptake that were comparable to those observed in the tumour.
FIGURE 9 – PCR analysis of apoptotic resgulator expression in
rMnSOD-treated cells. Ampliﬁcation of Bax and Bcl2 cDNAs from
MCF-7 cells treated or not treated with rMnSOD. Both samples were
prepared in triplicate. Panel a, lanes a, b and c show the ampliﬁed Bax
cDNA fragment (460 bp) from MCF-7 cells treated with rMnSOD.
Control lanes are d, e and f. Panel b, lanes a, b and c show the absence
of ampliﬁed Bcl2 cDNA fragments (205 bp) from MCF-7 cells treated
with rMnSOD. Control lanes are d, e and f. Panel c shows the actin
PCR product (500 bp) as control of cDNA quantity.
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4 times higher than those in normal organs, demonstrating the
speciﬁcity of the molecule to reach the tumour in the body.
The role the leader peptide has in these unusual oncotoxic func-
tions of rMnSOD was investigated by using synthetically con-
structed fragments. The ﬂuorescein-labelled leader peptide was
indeed able to permeate MCF-7 cells and exhibited a diffuse cyto-
solic distribution of ﬂuorescence. Moreover, the uptake of the
leader peptide was clearly inhibited when the target cells were pre-
viously treated with an excess of oestrogen. A scrambled FITC-
labelled peptide used as control could not permeate the tumour
cells. The function of the leader peptide was also assessed by
in vivo experiments. One hour after injecting the 68Ga-labelled
synthetic peptide, PET images of a dog suffering from spontane-
ous breast cancer showed that the peptide was localized in all the
lesions of the body, both primary and metastatic. Both of these
analyses conﬁrmed that the leader peptide might function as a mo-
lecular carrier, suggesting that the peptide moiety might be used
to transport several drugs and molecules into the tumour cells.
Moreover, the synthetic 68Ga-labelled peptide might also have a
role as a diagnostic and prognostic marker in conjunction with
PET scans and rMnSOD treatment.
Previous observations suggested that rMnSOD exerts its cyto-
toxic activity only on tumour cells expressing oestrogen receptors
(ER1). Although the molecular mechanism underlying rMnSOD
incorporation into tumour cells still needs to be fully clariﬁed, the
results reported in this article clearly demonstrate that the uptake of
both rMnSOD and the leader peptide is inhibited by the presence of
an excess of oestrogen. A possible explanation might be the seques-
tration of the cell surface forms of ER as a result of the oestrogen
excess, and thus impairing rMnSOD uptake. Alternatively, the es-
tradiol might affect the expression of other receptors responsible for
rMnSOD uptake. In any case, although these ﬁndings restrict the
range of activity of rMnSOD to ER1 tumour cells, the recombinant
molecule appears to be effective against ER1 tumours.
The speciﬁc and selective uptake of rMnSOD into tumour cells
was also conﬁrmed by injecting 131I-labelled rMnSOD into a
female dog affected by spontaneous breast cancer. These in vivo
results are in keeping with our previous pharmacological in vitro
observations10 and might have speciﬁc implications. If the most
important feature required for a cytostatic drug is the ability to
reach the tumour, then we could foresee a broad usage of rMnSOD
in cancer treatment. Besides functioning as an anti-tumoural drug,
which in itself could be considered a satisfactory result, the
recombinant protein and/or its leader sequence might also be used
both as a speciﬁc marker for image analysis and as a radiopharma-
ceutical vehicle. Indeed, the rMnSOD molecule can be labelled
with a beta or gamma emitter isotope and injected into an orga-
nism in which the presence of a tumour is suspected. The scinti-
graphic or PET examination of the organism will reveal the pres-
ence of a tumour as a result of the speciﬁc and selective uptake of
the labelled protein by the cancer cells. Moreover, a possible si-
multaneous therapeutic effect might be exerted by both the onco-
toxic property of the protein per se and the radioactive (gamma
and/or beta) emission of the protein-bound tracer. These possibil-
ities underline the diagnostic and therapeutic value of radiola-
belled rMnSOD as an anticancer agent. Experiments are in pro-
gress in our laboratory to use the labelled rMnSOD as an effective
means to combat and hopefully cure cancer, especially if used in
combination with more conventional treatments (surgery, chemo-
therapy and radiotherapy).
In conclusion, the present study gives strong evidence that
rMnSOD and its leader sequence deserve to be considered for the
treatment and diagnosis of cancer. In addition to the potent onco-
toxic and oncosuppressive effects supported by both in vitro and
in vivo experiments, this protein is the only human MnSOD avail-
able and can be produced in an active recombinant form and easily
administered to patients with tumours. Although the structural and
functional parameters of the molecule have been extensively char-
acterized, the tumour speciﬁcity still needs to be clariﬁed in more
detail, in particular regarding its correlation with the persistence
of the leader sequence and the involvement of oestrogen receptors.
Work is in progress to clarify the role of the leader sequence, espe-
cially to determine whether it is the key through which the mole-
cule is able to be taken up by ER1 cancer cells. If this is true, then
the intriguing possibility exists to deﬁne and use only the recogni-
tion peptide to deliver any kind of cytotoxic agent to the tumour
cells, ensuring and amplifying their cytotoxic effects, or to use it
as a carrier for gene therapy.
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